Weak start to FY2025-26, tough times ahead
12/02/26 -"CZM reported weak Q1 results, with challenges in both ophthalmology and microsurgery. Profitability declined significantly due to FX headwinds, an unfavourable product mix, and increased amortisation ..."
Pages
60
Language
English
Published on
12/02/26
You may also be interested by these reports :
05/03/26
Elekta’s Q3 profitability exceeded consensus expectations. Organic sales growth was recorded in EMEA and APAC, while the Americas exhibited weakness. ...
05/03/26
Amplifon reported another quarterly performance miss, with both sales and profitability falling short of the company-compiled consensus. Although the ...
04/03/26
We appreciate Clariane’s stronger-than-expected deleveraging and consider the 2026 targets easily achievable. However, the thin but consensus-beating ...
03/03/26
Given the company’s more tangible operational normalisation and earlier-than-expected exit from the accelerated safeguard plan, incorporating ...